

	WEDNESDAY 27-Jan-21	THURSDAY 28-Jan-21	TUESDAY 2-Feb-21 <a href="#">IAS COVID-19 Conference: Prevention</a>	WEDNESDAY 3-Feb-21	THURSDAY 4-Feb-21
			<a href="#">COVID-19 and the policy response</a> UTC 11:00-12:00 6am-7amET		
Satellite Sessions UTC 12:15-13:45 7:15am-8:45am ET	<a href="#">Ethical Considerations in HIV prevention trials: new guidance from WHO and UNAIDS</a>	<a href="#">Redefining success in the era of HIV biomedical prevention</a>		<a href="#">Layer, Compare, Combine: Emerging Concepts and Key Considerations for Next-Generation Trial Design</a>	<a href="#">Bringing PrEP to the people: Democratizing access to PrEP through differentiated delivery before, during, and after COVID-19.</a>
		<a href="#">Optimizing the delivery of HIV prevention services for maximum impact and sustainability: the Blantyre Prevention Strategy</a>		<a href="#">How have digital health technologies helped oral PrEP delivery for key and vulnerable populations during the COVID-19 pandemic and beyond?</a>	<a href="#">HIV vaccine R&amp;D in Europe</a>
		<a href="#">From Crisis to Fight Back: Assessing national progress on HIV prevention from the perspective of marginalised communities</a>		<a href="#">Helping data talk to you. The power of open access data sources</a>	<a href="#">Understanding and unpacking the results of the HPTN 071 (PopART) trial</a>
		<a href="#">Engaging Lake Victoria Fishing Communities in HIV Prevention Research: Lessons from Uganda, Kenya and Tanzania</a>	<a href="#">Nonpharmaceutical considerations in the prevention of COVID-19</a> UTC 13:00-14:00 8am-9amET	<a href="#">Effective Promotion of HIV Biomedical Prevention Strategies Amongst Black and African Migrant Communities in Europe, North America and Africa</a>	
Plenary Sessions UTC 14:00-14:45 9am-9:45am ET	<a href="#">HIV prevention 2021 – Where are we now and where are we going?</a>	<a href="#">More is better: Expanding the prevention pipeline</a>		<a href="#">It's about people: Prevention in the real-world</a>	<a href="#">Ready or not, the future is now</a>
	Lessons from concurrent pandemics: A two-way street (Tony Fauci)	Mother and child: HIV acquisition, immunity and new prevention strategies (Sallie Permar)		Viral networks and their implications for prevention policy (Christophe Fraser)	The past is prologue: Can lessons from the TasP trials point the way forward? (Leigh Johnson)
	Where will we be in 2025? (Winnie Byanyima)	Are we getting closer? Preventive vaccine and passive immunization strategies (Mark Feinberg)		Beginning with the end in mind: What we (think we) know about prevention user preferences (Ram Prasad)	What do we need to do now? (Wafaa El-Sadr)
	Reality check 2020: What is – and isn't – happening on the ground (Vuyiseka Dubula)	ARV-based prevention and the promise of MPTs (Sinead Delaney-Moretwe)		We're all in this together: Leaving no one behind in biomedical Px research (Adeeba Kamarulzaman)	What do we need now? (Nyasha Sithole)
Oral Abstract Concurrent Sessions UTC 15:00-16:00 10am-11am	<a href="#">OA1: Fitting an antibody: Mind the Fc</a>	<a href="#">OA7: Are we PrEPared?</a>	<a href="#">Active and passive vaccination to prevent COVID-19 infection and disease</a> UTC 15:00-16:00 10am-11am ET	<a href="#">OA13: Interacting pandemics: The impact of COVID on HIV research and programmes</a>	<a href="#">OA19: Mucosal immunology, microbiology and HIV susceptibility</a>
	<a href="#">HY01: Late-breaking Trial Results -- AMP and O84</a>	<a href="#">OA6: Multipurpose prevention technologies (MPTs) for prevention of HIV and pregnancy</a>		<a href="#">OA14: Pathways to maintaining HIV latency and suppression</a>	<a href="#">OA20: Fit to a T cell</a>
	<a href="#">OA2: Epidemiology: Using the basic science of implementation</a>	<a href="#">OA8: Building better bNAbs</a>		<a href="#">OA12: Gene-based vaccine approaches</a>	<a href="#">OA18: In vivo modulation of immune response to vaccination</a>
Invited-speaker Concurrent Sessions UTC 16:15-17:15 11:15am-12:15pm	<a href="#">SY1: First responders</a>	<a href="#">SY5: Reframing adherence</a>		<a href="#">SY7: Early vaccine clinical studies on native-like envelope trimers and germline-targeting immunogens</a>	<a href="#">SY8: B and T cells: Old players, new strategies</a>
	<a href="#">RT1: Coming soon to a clinic near you? The antibody infusion pipeline</a>	<a href="#">SY4: Getting the job done: Designing immunogens to induce broadly neutralizing antibodies</a>		<a href="#">RT2: Speed debating and STIs: People, programmes and pleasure</a>	<a href="#">SY9: An ambitious and advancing pipeline: T-cell and non-neutralizing antibody-based vaccine strategies</a>
	<a href="#">SY2: Achieving the unfulfilled promise of PMTCT</a>	<a href="#">SY3: Unconventional wisdom: Expect the unexpected</a>		<a href="#">SY6: In the beginning: Virus-host cell interactions</a>	<a href="#">SY10: One-stop shopping: Products, pathways and people</a>
Oral Abstract Concurrent Sessions UTC 17:30-18:30 12:30pm-1:30pm	<a href="#">OA4: PrEP via novel mechanisms of delivery: Into the unknown</a>	<a href="#">OA9: Integrating and optimizing cellular responses</a>	<a href="#">What's next for the COVID-19 response?</a> UTC 17:00-18:00 12pm-1pm ET	<a href="#">OA16: Bottoms up: New insights about rectal infections and HIV/STI prevention</a>	<a href="#">OA21: Implementation, interventions, impact</a>
	<a href="#">OA5: Innate immune responses: What's the latest?</a>	<a href="#">OA11: PrEP is here, considerations to achieve continued use</a>		<a href="#">OA17: Community engagement: Enabling responsive, inclusive, accountable research</a>	<a href="#">OA22: Mucosal transmission and immune responses</a>
	<a href="#">OA3: The clinical march of bNAbs</a>	<a href="#">OA10: Mapping policy: Accelerating progress locally, nationally and globally</a>		<a href="#">OA15: Env and platform designs to improve antibody responses</a>	<a href="#">RT3: Antibody Mediated Prevention trial: Where to from here?</a>
Satellite Sessions UTC 12:15-13:45 1:45pm-3:45pm ET	<a href="#">Getting to the Heart of Stigma: removing stigma as barrier and enhancing HIV prevention efforts</a>	<a href="#">The Future of PrEP: Developing Its Potential from Research to Implementation</a>		<a href="#">Vaccines: What HIV R&amp;D did for COVID-19</a>	
	<a href="#">HIV &amp; TB: An R&amp;D tale of two vaccines</a>	<a href="#">HIV phylogenetics as a tool for focussed prevention</a>		<a href="#">Advancing Novel HIV Prevention Strategies, Together: A Scientific and Community Exchange</a>	
				<a href="#">Engagement of African Men and Transgender Women Who Have Sex with Men in HIV Research</a>	